Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07565506Phase 2Not Yet Recruiting

Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU

Role: lead

NCT06020235Phase 2Not Yet Recruiting

Nu-3 Gel for Infected Diabetic Foot Ulcers

Role: lead

NCT05276401Phase 2Terminated

Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer

Role: lead

NCT02737722Phase 1Completed

Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus

Role: lead

All 4 trials loaded